Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett sits down with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). The trial, which included patients with relapsed or refractory AML, demonstrated a 40% response rate, exceeding the efficacy threshold. The open-label trial combined intravenous RC110 bisantrene with chemotherapies clofarabine and fludarabine. Out of the treated patients, five experienced complete responses and one had a partial response, surpassing the goal of at least three complete responses. Tillett expressed gratitude to Professor Nagler and the Chaim Sheba Medical Centre team for their dedication over the past five years. The team’s efforts have contributed significantly to the historical evidence supporting bisantrene’s efficacy and have spurred further interest among clinicians. The company plans to initiate a new Phase 1/2 investigator-sponsored trial using RC220 bisantrene, a reformulated version, to meet the high unmet needs of AML patients. Race Oncology is focused on anthracycline combinations, aiming to provide cardio-protection and enhanced anticancer activity in solid tumours, as well as offering low-intensity treatment options for AML. #ProactiveInvestors #RaceOncology #ASX #AML, #CancerTreatment, #Bisantrene, #ClinicalTrials, #PharmaNews, #OncologyResearch, #ChemoTherapy, #CancerResearch, #HealthNews, #MedicalResearch, #Phase1Trial, #Phase2Trial, #AcuteMyeloidLeukemia, #CancerCare, #MedicalBreakthrough, #Oncology, #Hematology, #DrugDevelopment, #PatientCare #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews